9 July 2020
BioAgilytix, a leading provider of contract bioanalytical testing services with specialization in large molecule bioanalysis, today announced that Chad Briscoe, Ph.D. has joined the organization’s leadership team as Chief Scientific Officer. In this role, Dr. Briscoe will provide scientific and regulatory oversight to BioAgilytix’s global teams with strategic guidance in line with emerging scientific developments.
Dr. Briscoe is a seasoned scientific executive with nearly 25 years of experience leading operational and scientific innovation in the bioanalytical and biomarker segments of the pharmaceutical industry. Prior to joining BioAgilytix, Dr. Briscoe was executive director of global bioanalytical science for a large contract research organization, where he was responsible for global laboratory scientific strategy including team leadership and key client relationship oversight. Today he is a recognized global expert and thought leader in areas including regulated bioanalysis, analytical instrument qualification, and biomarker analysis with immunoassays, flow cytometry, and genomics techniques. Dr. Briscoe is also a sought-after speaker at industry events such as WRIB, the Global CRO Council, Land O’ Lakes, Global Bioanalysis Consortium, APA, APS, CPSA, and ASMS, and is often requested to participate in industry forums as a collaborator and mentor.
“It is with great excitement that we welcome Chad to the BioAgilytix team,” said Jim Datin, President and Chief Executive Officer of BioAgilytix. “Not only is he an esteemed bioanalytical thought leader, but also a driven problem-solver with a long track record helping pharma and biotech innovators bring their drugs to market efficiently. His leadership will be a great asset to our customers in helping them better plan for and execute the bioanalytical aspects of their clinical trials, and in guiding our team to deliver robust but practical solutions that successfully address the ever-increasing complexities of large molecule drug development.”
“Over the course of my career, I have developed a true passion for the indispensable role of bioanalytical scientists in the drug development process – and I’m thrilled to now be able to collaborate with and guide one of the most talented, dedicated scientific teams I’ve ever had the opportunity to work with,” said Dr. Briscoe. “We’re collectively committed to helping customers bring new drugs to market faster, and it will be exciting to take on new bioanalytical challenges alongside these colleagues.”
